Bangladeshi Firm Beximco Launches Generic Trikafta at 96% Discount, Exploiting WTO Patent Waiver for Cystic Fibrosis Patients
核心洞察
Beximco Pharmaceuticals (搜索) has reverse-engineered Vertex's Trikafta, launching generic Triko (搜索) at approximately $12,750 per year versus the US list price of roughly $370,000.
The company utilized the WTO TRIPS waiver for Least Developed Countries to legally manufacture the cystic fibrosis (搜索) therapy without facing patent litigation.
The initiative began in 2022 after patient advocacy group Right to Breathe (搜索), representing families from Ecuador, South Africa, Brazil, India and the UK, approached Beximco.
A Bangladeshi pharmaceutical company has shattered the monopoly on one of the world's most expensive medications, offering a cystic fibrosis (搜索) treatment at roughly 96% less than the innovator product. Beximco Pharmaceuticals (搜索) has reverse-engineered Vertex Pharmaceuticals' breakthrough drug Trikafta (marketed as Kaftrio in some countries) and launched a generic version under the brand name Triko (搜索), exploiting a critical legal provision under international trade law.
The move directly challenges Vertex's pricing strategy, which charges approximately $370,000 for a year's supply in the United States. Beximco's generic alternative costs about $12,750 per patient annually, according to company Chief Operating Officer Rabbur Reza.
The Legal Framework Behind Triko (搜索)
Beximco's ability to manufacture and sell Triko (搜索) rests on the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Under this framework, designated Least Developed Countries like Bangladesh are granted specific waivers exempting them from enforcing pharmaceutical patents. This allows Bangladeshi laboratories to legally reverse-engineer complex Western therapeutics without facing immediate intellectual property litigation from multinational corporations.
"This is not charity," Reza said. "It is about proving that patients have a right to access life-saving medicine."
However, Reza cautioned that after Bangladesh's graduation from LDC status, producing similar medicines without licensing or royalty agreements is expected to become more difficult, raising questions about the long-term sustainability of this access model.
A Patient-Driven Initiative
The development of Triko (搜索) began in 2022 after patient advocacy group Right to Breathe (搜索), representing families from Ecuador, South Africa, Brazil, India and the UK, approached Beximco to inquire whether the company could develop a more affordable version of the treatment.
After nearly three years of research and laboratory work, Beximco developed its version under an internal project called "Equibreath" and completed comparisons with the innovator product. The first small-scale handover took place in June. Reza said the company absorbed the research and development costs and currently sells the medicine close to cost.
The Human Dimension
The human cost of restricted access is exemplified by patients like Josua Lottering, an 18-year-old from the Western Cape of South Africa. With his lung capacity severely reduced by the progressive genetic disorder, his family found it impossible to finance the Vertex medication. The Lottering family undertook a journey to Dhaka, Bangladesh, joining a growing network of international patients traveling to South Asia to purchase Triko (搜索) directly from the Beximco production line.
Cystic fibrosis (搜索) causes thick, sticky mucus to build up in the lungs and digestive tract. Trikafta, since its launch in 2019, has dramatically improved lung function and extended life expectancy by decades for those who can access it. Vertex has generated an estimated $49 billion from its cystic fibrosis franchise to date.
A Broader Industry Transformation
The Triko (搜索) development is part of a wider shift in Bangladesh's pharmaceutical industry, which now meets about 98% of domestic demand and exports medicines to around 166 countries, generating more than $200 million annually. The industry is increasingly targeting complex medicines including biologics, immunotherapies, and treatments for rare diseases.
The situation mirrors the early 2000s battle over antiretroviral drugs for HIV/AIDS, when Indian generic manufacturers defied Western monopolies to supply affordable medication to the African continent. More than a decade ago, Bangladesh similarly exploited the TRIPS waiver to produce generic versions of the breakthrough Hepatitis C drug sofosbuvir, which had entered the US market at about $1,000 per tablet.
Implications for Global Health Equity
For health ministries across developing nations where advanced therapeutics remain unavailable due to prohibitive patent pricing, the Bangladesh model offers a potential blueprint. Public health advocates argue that Vertex's refusal to implement tiered pricing models for developing nations forces patients to rely on cross-border access to obtain life-saving medication.
As Reza stated: "When a medicine exists but cannot reach the people who need it, its purpose remains unfulfilled."